SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics Stock Analysis & Ratings
SAGE Stock Chart & Stats
Day’s Range$32.26 - $34.479
52-Week Range$27.36 - $79.45
Previous Close$32.22
Volume684.54K
Average Volume (3M)677.00K
Market Cap$2.02B
P/E Ratio-4.1
Beta1.56
Next EarningsAug 03, 2022
EPS Forecast-$2.07
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target$53.31
Smart Score6
EPS (TTM)-8.23
SAGE Therapeutics News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $27.36 and its highest was $79.45 in the past 12 months.
What is SAGE Therapeutics’s market cap?
SAGE Therapeutics’s market cap is $2.02B.
What is SAGE Therapeutics’s price target?
The average price target for SAGE Therapeutics is $53.31. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $85.00 ,the lowest forecast is $35.00. The average price target represents 56.20% Increase from the current price of $34.13.
The highest analyst price target is $85.00 ,the lowest forecast is $35.00. The average price target represents 56.20% Increase from the current price of $34.13.
What do analysts say about SAGE Therapeutics?
SAGE Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Aug 03, 2022 which is in 77 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on May 03, 2022. The company reported -$2.07 earnings per share for the quarter, missing the consensus estimate of -$2.057 by -$0.013.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 59,070,000 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$2.07 in its last earnings report, missing expectations of -$2.057. Following the earnings report the stock price went up 0.583%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is PRIMECAP Management Co. It holds SAGE Therapeutics’s shares valued at 2M.
---
SAGE Therapeutics Stock Analysis
Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Price Target
$53.31
Moderate Buy▲(56.20% Upside)
Analyst Forecast
Moderate Buy
Average Price Target: $53.31
Blogger Sentiment
Neutral
SAGE Sentiment 50% Sector Average 71%
Hedge Fund Holdings
▼ Decreased
By 12.8K Shares Last Quarter.
Insider Transactions
▲ Bought Shares
Worth $273.4K over the Last 3 Months
Retail Investors
Very Negative
Last 7 Days ▼ 1.0% Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish 50% Bearish 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.08%
12-Months-Change
Fundamentals
Return on Equity
-26.74%
Trailing 12-Months
Asset Growth
-18.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
Company
Price & Change
Follow
Marinus
―
Ovid Therapeutics
―
Ligand Pharma
―
Neurocrine
―
Anavex Life Sciences
―
---